SOPHIA ANTIPOLIS, France, March 29 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that additional information has been communicated by Pfizer Inc regarding the design of the first clinical study for PF-03187207 in patients with glaucoma and ocular hypertension.
NicOx announced the initiation of this clinical trial on March 28, 2007. The disclosures which have been made by Pfizer specify that this trial is a phase 2, dose-finding study, which is designed to compare the safety and the efficacy of PF-03187207 to latanoprost.
The trial will be a 28 day, parallel group, randomized and double-masked study, which is expected to enroll around 150 patients with primary open angle glaucoma, or ocular hypertension, in one or both eyes.
The primary endpoint of the study will be the change in diurnal intraocular pressure (IOP) at day 28. Secondary endpoints will include: the change in IOP from baseline at the study center visits on day 7, 14, 21 and 28, the proportion of patients at target IOP across all study visits, in addition to safety evaluations.
PF-03187207 is the selected development compound generated under the August 2004 collaboration agreement between Pfizer and NicOx which is focused on the research and development of nitric oxide-donating prostaglandin F2- alpha analogs for the treatment of glaucoma.
For more details, refer to the website of Clinical Trials.gov at the following address: http://www.clinicaltrials.gov/ct/show/NCT00441883?order=4
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of pain and inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes.
NicOx has strategic partnerships with some of the world’s leading pharmaceutical companies, including Pfizer Inc. and Merck and Co., Inc.
NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext(TM) Paris (segment: Next Economy).
The elements included in this communication may contain forward-looking statements subject to certain risks and uncertainties. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risks factors described in the company’s document de reference.
CONTACTS: http://www.nicox.com
NicOx S.A.
CONTACT: Karl Hanks, Manager of Corporate Relations and Market Analysis,of NicOx, +33-0-4-97-24-53-42, hanks@nicox.com; or Investors in the UnitedStates: Lisa Burns, lburns@burnsmc.com, or Laura Siino, lsiino@burnsmc.com,both of Burns McClellan for NicOx, +1-212-213-0006; or Media: JonathanBirt, +1-212-850-5634, jbirt@fd-us.com, or Julia Phillips,+44-0-20-7831-3113, julia.phillips@fd.com, both of FD for NicOx
Web site: http://www.nicox.com/
